Neurasthenia in a longitudinal cohort study of young adults by Merikangas, K. & Angst, J.
Psychological Medicine, 1994, 24, 1013-1024. Copyright © 1994 Cambridge University Press
Neurasthenia in a longitudinal cohort study
of young adults
K. MERIKANGAS1 AND J. ANGST
From the Genetic Epidemiology Research Unit, Yale University School of Medicine, New Haven, CT, USA;
and Psychiatric University Hospital, Zurich, Switzerland
SYNOPSIS This study examines the concept of neurasthenia in a longitudinal cohort of young
adults selected from a community sample of the canton of Zurich, Switzerland. The major focus is
on the validity of the case definition of neurasthenia. Close approximations of the proposed
descriptive and research definitions of the ICD-10 are employed as well as the concept of'irritable
weakness' as described in 1831 by Kraus (1926-1932).
The prevalence of neurasthenia defined according to the ICD-10 criteria was: 1 % across 10 years
and 0-9% in 1988 for a duration criterion of ^ 3 months; and 81 % across 10 years and 12% in
1988 for a duration criterion of ^ 1 month. The duration criterion of ^ 3 months appeared to be
excessively restrictive to represent individuals with neurasthenia in the community. Subjects with
1 month episodes of neurasthenia exhibited sufficient differences from controls and similarities to
subjects with anxiety or depressive disorders to justify a 1 month duration criterion for neurasthenia
in community samples.
The clinical significance of neurasthenia was indicated by the magnitude of subjective distress,
and occupational and social impairment reported by the majority of the cases. Prospective
assessment of the longitudinal course of neurasthenia revealed that approximately 50 % of the cases
continued to exhibit this disorder at follow-up. Our findings suggest that neurasthenia is equally
likely to represent an early manifestation of affective illness as it is a consequence in those
neurasthenic subjects who exhibited comorbid affective disorders. The magnitude, chronicity,
impairment, longitudinal stability and distinction from anxiety and depression associated with this
condition in the general population, suggest that neurasthenia is an important diagnostic entity for
which additional validation studies should be undertaken.
INTRODUCTION Definition
With the recent focus on chronic fatigue syn- Beard's description of this syndrome included
drome, there has been a resurgence of interest in the following criteria: general malaise, debility
the concept of neurasthenia (Costa e Silva & De of all the functions, poor appetite, abiding
Girolamo, 1990; Wessely, 1991). Although weakness in the back and spine, fugitive neur-
Beard, the American neurologist, is credited algic pains, hysteria, insomnia, hypochondria,
with the introduction of the term'neurasthenia' disinclination for consecutive mental labour,
in 1869 to describe a syndrome characterized by severe and weakening attacks of sick headache,
exhaustion of the nervous system, various forms and other analogous symptoms. He also required
of nervous asthenia have been described through- that anaemia and other organic diseases be
out the history of medicine (Costa e Silva & excluded (Beard, 1869).
De Girolamo, 1990). The definition of neurasthenia has generally
been vague and broad. Although the key features
of physical and mental fatigue are generally
' Address for correspondence. Dr K. MerikangasGenetic Epi-
 i n d u d e d i n m o s t definitions, the Specific COn-
demiology Research Unit, Yale University School of Medicine, 40 . ' .
Temple street, New Haven, CT 06510, USA. comitant symptoms are highly variable. The
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Table 1. International Classification of Disease-
10 criteria for F48.0 neurasthenia
A Either of the following must be present:
(1) Persistent and distressing complaints of feelings of
exhaustion after minor mental effort (such as performing or
attempting to perform everyday tasks that do not require
unusual mental effort);
(2) Persistent and distressing complaints of feelings of fatigue and
bodily weakness after minor physical effort.
B At least one of the following symptoms must be present:
(1) feelings of muscular aches and pains
(2) dizziness
(3) tension headaches
(4) sleep disturbance
(5) inability to relax
(6) irritability.
C The patient is unable to recover from the symptoms in criterion
A (/) or (2) by means of rest, relaxation, or entertainment.
D The duration of the disorder is at least 3 months.
E The disorder does not occur in the presence of organic emotion-
ally labile disorder, post-encephalitic syndrome, post-
concussional syndrome, mood (affective) disorders, panic
disorder, or generalized anxiety disorder.
major difference between some of the more
recent definitions of the condition and the
descriptions of the neurologists of the nineteenth
and early twentieth centuries is the inclusion of
'nervous irritability' as a key feature of the
condition. A cluster analysis of the symptoms of
subjects from the general community conducted
by Angst & Koch (1991) yielded the same three
distinct factors that have been the key features
of clinical descriptions of neurasthenia, namely,
physical exhaustion, mental fatigue and nervous
irritability.
Although the symptoms of chronic fatigue
syndrome (CFS) are quite similar to those cited
above for neurasthenia, the major difference
between the two definitions is the requirement of
myalgia for CFS (Wessely, 1991). The aetiology
of CFS has often been attributed to viral
infections as in the post-viral fatigue syndromes
(i.e. chronic Epstein-Barr infection, Tobi et al.
1982); however, evidence that the characteristic
physical and mental fatigue are induced by viral
infection is still lacking (Holmes et al. 1988).
Aetiological theories of neurasthenia are
nearly as numerous as the physicians who de-
scribed the disease: horseback riding (Hippo-
crates, in Roccatagliata, 1973); metabolic
factors including glucose metabolism, pitui-
tary dysfunction, and thyroid abnormalities
(Mirouze, 1962); life stress (Beard, 1869); drug
abuse (Beard, 1869); sexual excesses (Freud,
1895); genetic factors (Mobius, 1894; Costa e
Silva & De Girolamo, 1990); personality
factors; and psychiatric disorders, particularly
depression. However, most contemporary for-
mulations require exclusion of organic abnor-
malities in order to diagnose neurasthenia.
Association between neurasthenia and somatic
disturbances
A variety of non-psychiatric syndromes have
been associated with neurasthenia. Beard (1869)
described stomach disturbances, migraine, men-
strual disorders, back pain, and respiratory
problems. Although most of the diagnostic
criteria for neurasthenia rule out discrete organic
causes of the syndrome, the above-cited somatic
disturbances tend to comprise symptoms rather
than pathognomonic manifestations of a specific
disease.
Association between neurasthenia and
psychiatric disorders
An association between neurasthenia and the
'neurotic' psychiatric disorders has been
reported in both descriptive literature and
systematic studies of clinical samples. The three
most frequently cited disorders are depression,
anxiety, and somatization. In the classic essay in
which he first described 'Anxiety Neurosis',
Freud contended that Beard's formulation of
the concept of neurasthenia was too broad to be
clinically meaningful. His definition of genuine
neurasthenia excluded the hereditary nervous
disorders and the 'pseudo-neurasthenias'
induced by physical diseases, as well as mel-
ancholia and anxiety neurosis (Beard, 1869).
Thus, Freud provided the first clear discrimi-
nation between neurasthenia and anxiety neur-
osis and melancholia (Freud, 1895). Freud's
observation was recently confirmed by a multi-
variate analysis by Goldberg et al. (1987), who
demonstrated that a symptom cluster charac-
terized by fatigue can be distinguished from
those with anxiety and depression.
The proportions of neurasthenics who also
exhibit a psychiatric disorder range from one-
half to three-quarters in psychiatric samples
(Allan, 1944; Taerk et al. 1987; Manu et al.
1988; Strauss, 1988; Swartz, 1988; Kruesi et al.
1989; Wessely & Powell, 1989; Hickie et al.
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1990), and from one-third to one-half in primary
care settings (Katon & Walker, 1993). Katon &
Walker (1993) reported that the association
between fatigue and anxiety and depression
increases as one moves from the community to
primary care to tertiary care facilities. This
suggests that neurasthenics with psychiatric
disorders are more likely to seek treatment than
those without comorbid conditions.
Previous analyses of this sample revealed that
50 % of the neurasthenic subjects had a history
of anxiety or depression. Moreover, the persons
with extended neurasthenia had nearly twice the
degree of comorbidity with the latter disorders
than did those with recurrent brief neurasthenia
(Angst & Koch, 1991).
Personality and neurasthenia
In a study of the pre-morbid personality of
neurasthenics who had sought treatment for this
condition, Nystrom & Lindegard (1975) found
that although sub-validity, or psychasthenia, was
associated with neurasthenia, even greater as-
sociations emerged between psychasthenia and
anxiety and depression. This suggests that
personality factors comprise non-specific and
independent risk factors for the subsequent
development of these syndromes. More recently,
Blakely et al. (1991) examined psychiatric symp-
toms and personality in patients with CFS and
chronic pain compared to normal controls. In
classifying the patients on both the symptom
and personality scales, they found several
clusters of CFS patients, one of which had no
evidence of psychiatric or personality disorder.
Moreover, their data suggested that emotionality
is a predisposing factor rather than a reaction to
neurasthenia (Blakely et al. 1991). However,
these findings require replication in a prospective
study of a more systematic sample.
Treatment of neurasthenia
In accordance with the multiple causative factors
which have been implicated for neurasthenia,
numerous forms of treatment have been
suggested as well. For example, Beard (1869)
recommended general electrization (i.e. electric
shocks applied over the head and spine), whereas
Vittoz (1903) applied 'brain control'. Anti-
depressants are the most widely employed agents
in the contemporary treatment of neurasthenia
or CFS (Wessely, 1991).
Current studies of neurasthenia
The diagnostic criteria for research on neur-
asthenia in the most recent version of the
International Classification of Disease, Edition
10 (WHO, 1993) are presented in Table 1. The
chief criteria are as follows: (a) persistent fatigue
after ordinary tasks; (b) one of six symptoms;
(c) inability to recover after rest; (d) duration of
at least 3 months; and (e) exclusion of con-
comitant anxiety and depressive syndromes, and
specific organic syndromes. The distinction
between neurasthenia and anxiety /depression
described by Freud (1895) has been adopted in
the ICD-10 as well; concurrent anxiety and
depression preclude a diagnosis of neurasthenia.
The emergence of CFS as a significant disease
entity has led to the generation of numerous
studies investigating the clinical phenomenology
and associated features of this condition. Com-
munity studies of fatigue and fatigability have
provided preliminary evidence of the magnitude
of this complaint in the general population.
Although variation in sampling methods pre-
cludes derivation of accurate aggregate rates
across studies, the current prevalence of fatigue
is approximately 24 % in community studies and
15 % in primary care settings (Lewis & Wessely,
1992). Although there is a greater proportion of
women with fatigue, there is still a substantial
proportion of males who complain of fatigue.
The most important finding from these studies is
the substantial degree of global dysfunction and
chronicity associated with fatigue (Kroenke et
al. 1988; David et al. 1990; Cathebras et al.
1992). However, the degree to which the findings
regarding the symptom of fatigue generalize
with those with the syndrome of neurasthenia
needs to be examined.
Although there are several studies currently
investigating the prevalence of the ICD-10
disorders in the community and in primary care
settings under the auspices of the WHO, to our
knowledge, there are no published data from
epidemiological samples on the magnitude or
correlates of this condition in the general
population. The major purpose of the present
study is to assess the validity of the case definition
of neurasthenia. Close approximations of the
proposed descriptive and research definitions of
the ICD-10 (WHO, 1993) are employed as well
as the concept of 'irritable weakness' as de-
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scribed by Kraus (1926-1932). Therefore, the
goals of the present study were as follows.
(1) To estimate the magnitude and demo-
graphic distribution of neurasthenia in a pro-
spective study of a cohort selected from the
general population.
(2) To test the applicability of the ICD-10
definition of neurasthenia in an epidemiological
sample through systematic assessment of the
inclusion and exclusion criteria and their val-
idity.
(3) To examine the association and longi-
tudinal course of psychiatric disorders and
neurasthenia.
(4) To examine the clinical and social
manifestations of neurasthenia and its longi-
tudinal stability.
METHOD
Subjects
The subjects of this report are a cohort of 29-30-
year-olds from Zurich, Switzerland. The sample
was originally selected in 1978 according to
scores on a screening test of current symptoms,
the Symptom Checklist 90 (SCL-90-R), from
which high and low risk groups were selected.
The SCL-90-R was developed by Derogatis
(1977) as a self-report inventory about current
psychiatric symptoms. It is a 90-item multi-
dimensional symptom inventory that yields
scores on nine symptom dimensions. The sample
was first interviewed in 1979 at age 20, with
three subsequent interviews in 1981, 1986, and
1988. The subjects in this report are comprised
of 424 subjects (200 males and 224 females) who
were interviewed directly in 1988. A more
detailed description of the sampling procedures
is given by Angst et al. (1984) and Merikangas et
al. (1990).
Procedure
A direct interview, the Structured Psychopatho-
logical Interview and Rating of the Social
Consequences for Epidemiology (SPIKE), was
administered by psychiatric residents and clinical
psychologists with extensive clinical training.
This interview schedule assesses a number of
somatic syndromes, including headache, gas-
trointestinal, cardiovascular, and respiratory
syndromes, as well as psychological syndromes
including depression, phobia, obsessive-com-
pulsive, anxiety, and substance abuse (Angst et
al. 1984). Psychiatric diagnoses were made
according to both the DSM-III and the DSM-
III-R Criteria (American Psychiatric Associ-
ation, 1980, 1987). Screening probes were
administered for each section and symptoms,
duration, frequency, severity, and treatment
history and impairment are assessed for every
positive answer. Personal and family history of
the syndromes were also assessed for all subjects,
irrespective of endorsement of the diagnostic
screening question for each section.
Symptoms of neurasthenia
Symptoms of neurasthenia were collected at all
four interviews. Because the interviews were
developed prior to the introduction of the ICD-
10, only two of the symptomatic criteria in
Section B were collected in the diagnostic
interview, namely sleep disturbances and ir-
ritability. Therefore, we required at least one of
these symptoms for the diagnosis of neuras-
thenia. The other symptoms of neurasthenia
were assessed in the SCL-90, which was ad-
ministered at the time of each of the four
interviews. However, the vast majority of sub-
jects complaining of persistent weakness and
fatigue met more than half of the symptomatic
criteria for neurasthenia. Organic causes of
neurasthenic symptoms could not be excluded in
our data.
Impairment and severity were assessed in two
ways: (/) as an analogue rating from 0-100, with
0 representing no impairment (i.e. no inter-
ference with daily activities or the absence of
suffering or distress from the symptoms), and a
score of 100 representing complete incapaci-
tation or extreme suffering or distress from the
symptoms; and (2) as a categorical scale from
1-5, with descriptions to anchor each level of
severity or impairment.
Assessment of personality
The Freiburg Personality Inventory (FPI) is a
212-item personality questionnaire designed to
measure 9 primary factors including nervous-
ness, aggressivity, depressiveness, excitability,
sociability, temperament and striving for domi-
nance, inhibition and frankness (Fahrenberg et
al. 1970). In addition to three secondary factor
provided by the test developers, three factors
derived from a factor analysis of very large
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Table 2. Weighted longitudinal and \-year prevalence rates of neurasthenia by components of
JCD-IO definition
Neurasthenia groups
Symptoms* + Duration > 3 months* + Anxiety/depressiont
Symptoms + Duration > 3 months^
Symptoms + Anxiety/depression
Symptoms only*
Anxiety/depression, No symptoms*
None of the above
1979
0-7
10
2-3
2-6
118
81-6
1981
01
0-6
1-5
1-8
17-1
78-9
1986
11
0-2
5-9
5-4
17-3
701
1988
21
0-9
2-5
7-6
16-6
70-3
Total
3-7
10
11-4
70
25-3
51-6
* One of ICD-10 symptom criteria for neurasthenia.
f DSM-III-R anxiety or affective disorder.
t ICD-10 definition of neurasthenia.
samples at the Zurich site were also employed,
namely extraversion, autonomic lability, and
aggressivity (Angst & Clayton, 1986).
Statistical analyses
In the present study, the statistical analyses that
were conducted to test the significance of the
differences for comparisons of the categorical
variables were x2 corrected for continuity.
Analyses of variance were applied to the
continuous variables using the general linear
models procedure of the Statistical Analysis
System (Reinhardt & Winston, 1985). Group
mean differences were compared with the
Duncan Multiple Range Test, which corrects for
chance (Duncan, 1975).
RESULTS
Assessment of diagnostic criteria
Table 2 presents the weighted and longitudinal
rates of neurasthenia according to the step-wise
application of the ICD-10 criteria for neur-
asthenia. The figures in the second row labelled
'symptoms and duration ^ 3 months' represent
the subjects who met all of the ICD-10 criteria
for neurasthenia (i.e. persistent fatigue, ^ 1 of
the 6 symptoms, inability to recover, plus > 3
months duration and the absence of concomitant
anxiety or depressive disorders) at each of the 4
interviews and across the entire study interval.
Inspection of longitudinal trends shown in Table
2 revealed that the rates of neurasthenia were
quite stable over 10 years at 1 %. However, there
was an increase over time in the proportion of
subjects who reported symptoms of neurasthenia
as the sample aged from 20 to 30. Inspection of
the sex ratio across the 10 years of follow-up
revealed that the prevalence of neurasthenia was
equal among males and females during the
initial stages of the study, whereas females
exhibited 1-6-fold greater rates of neurasthenia
than males during the later interviews.
Application of successive criteria of exclusion
of subjects with anxiety or depressive disorders
and duration of ^ 3 months to the proportion
of subjects with neurasthenic symptoms yielded
a dramatic decrease in the longitudinal rates of
neurasthenia from 23'1 % to 1 %. This indicates
that nearly 75 % of individuals complaining of
persistent and distressing fatigue and weakness
with symptomatic manifestations are excluded
from the diagnosis of neurasthenia. Because the
3 month duration criterion yielded groups that
were too small for meaningful analysis, a 1
month duration was employed in subsequent
analyses. The major focus of this paper is
therefore on determining whether differences
exist between pure and comorbid cases of
neurasthenia. There were no differences between
the four groups in demographic characteristics
including marital status, education, number of
children and social class.
Symptoms
The non-criterial symptoms of neurasthenia
collected in the diagnostic interview and self-
reported criterial symptoms according to co-
morbid anxiety and depression in neurasthenic
subject, at the most recent interview are
presented in Fig. 1. No major differences in
symptom frequencies emerged between the co-
morbid and non-comorbid neurasthenics. The
large proportion of neurasthenic subjects who
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• Stress tolerance1
• Concentration1
I Sensitivity to criticism1
t Sensitivity to ext. stimuli1
Inability to relax2
Tension headaches2
Muscle aches/pains2
Dyspepsia2
Dizziness2
Sleep disturbances'
Irritable1
20 40 60
% of subjects with neurasthenia
100
FIG. 1. Symptoms of neurasthenia by neurasthenia comorbidity groups in 1988. ( • . Anxiety/depression + neurasthenia;
H, neurasthenia only; ' = interview; and 2 = SCL-90 self-report.)
Table 3. SCL-90 scores^ in neurasthenia by comorbidity groups in 1988
Scale scores
Anxiety
Depression
Hostility
Interpersonal sensitivity
Obsessive compulsive
Paranoia
Phobia
Psychoticism
Factor scores
Somatic instability
Emotional instability
Vegetative instability
Global severity index
Neurasthenia
+ Anx/dep
(AT =32)
Mean (s.D.)
60-3 (11-43)
66-1(11-73)
55-9(13-96)
66-4(13-40)
63-3 (13-40)
62-6(10-66)
60-9(11-43)
64-2(11-96)
65-2 (9-68)
60-9 (1014)
58-4(7-91)
65-0(11-30)
Neurasthenia
only
(A-= 51)
Mean (s.D.)
56-1 (8-3)
60-7 (7-2)
55-6(10-0)
60-8 (914)
54-9(10-8)
571 (1013)
55-1(12-4)
57-7 (1004)
53-2(10-98)
55-6 (6-99)
56-1 (8-26)
58-9 (7-39)
Anx/dep
only
(N = 74)
Mean (s.D.)
55-9(1413)
611 (120)
56-3 (10-7)
60-8(13-66)
56-4(12-99)
56-7(11-62)
55-8 (12-26)
57-0(12-02)
52-8 (10-67)
56-3(9-91)
55-8 (8-79)
60-2(11-31)
Neither
(N = 267)
Mean (s.D.)
50-4(11-28)*'
53-8(10-92)*'
51-5 (10-33)*'
54-9(11-56) • '
50-9(11-56)*'
53-2(11-55)*
50-3 (11-37)*'
531 (10-41)**
48-6 (9-42)"
50-8 (9-43) • •
51-2(8-11)**
53-8 (9-17)"
t / transformed (mean = 50, s.D. = 10).
reported decreased stress tolerance, and
increased sensitivity to criticism and to external
stimuli (i.e. 82%, 73% and 67%, respectively)
suggests that these phenomena may constitute
additional features of neurasthenia. In contrast,
the criteria of muscle aches and pains, dys-
pepsia, and dizziness were reported by less than
one-third of the subjects with neurasthenia,
suggesting that they may not comprise valid
clinical features of this condition.
The factor and scale scores of the SCL-90 in
the neurasthenia groups and controls are shown
in Table 3. All three groups of affected subjects
differed significantly from the unaffected subjects
on all of the scale scores and factor scores of the
SCL-90. The comorbid group exhibited the
greatest scores on all scales, whereas the groups
of subjects with either neurasthenia alone or
anxiety/depression alone had nearly identical
scores on all scales. This suggests a lack of
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Table 4. Clinical features of neurasthenia by
comorbidity in 1988
Maximal duration/episode (past year '
^ 1 week
> 1 week-l month
S 1 month
Subjective distress
mean (s.D.)
Attribution (%)
Physical
Psychological
Impairment (%)
Occupational
Social
Dimensional rating, mean (s.D.)
Professional treatment
Past year (%)
Lifetime, mean (s.D.)
• P < 0 0 5 : *• P
Neurasthenia Neurasthenia
+ Anx/dep
( # = 3 2 )
281
6-3
65-6
25-8
(25-7)
22-6
96-8
80-6
93-5
39-7
(29-0)
41-9
0-7
(0-83)
only
(#=51)
66-7
19 6 **
13-7
53-7
(280)
30-2
721 **
79-1
860
33-9
(25-6)
23-3
0-3 *
(0-69)
specificity of the SCL-90 scale scores for both
neurasthenia and affective disorders.
Clinical features
The clinical features of neurasthenia in the two
groups of subjects during the year prior to the
most recent interview are presented in Table 4.
Patterns of duration of neurasthenic episodes
differed for the comorbid and non-comorbid
groups. The majority of subjects in the non-
comorbid group reported episodes of approxi-
mately one week, but occurring frequently over
the one year period. In contrast, the majority of
the comorbid subjects reported longer episodes,
lasting an average of 1-2 months, but with less
frequency than the non-comorbid group.
The degree of subjective distress attributed to
neurasthenia was similar for the two groups of
subjects. The magnitude of the distress was
rated on an analogue scale from 0, indicating no
distress, to 100 for extreme distress. The high
mean levels found in both groups suggest that
the symptoms of neurasthenia are associated
with a severe degree of distress in all of the
subjects who meet the criteria for this syndrome.
Likewise, there was a remarkable degree of
subjective and occupational impairment associ-
ated with neurasthenia among all affected
persons. Approximately 80% of the cases
reported that neurasthenia symptoms interfered
with their ability to pursue their usual occu-
pational activities. The mean level of 80 (range
0-100) suggests that the complications of neur-
asthenia were sufficient to inhibit routine daily
activities. Similar findings emerged for the
dimensional measures of impairment in both
occupation and social activity.
The proportion of subjects who had sought
treatment differed significantly between the
comorbid and non-comorbid groups. The treat-
ment rates among the comorbid cases were
similar to those of the anxiety and depression
group, with 42% reporting having sought
Table 5. Rates of somatic and psychiatric disorders by neurasthenia comorbidity groups in 1988
Somatic disturbances (%)
Back
Circulation
Menstrual (females only)
Migraine
Respiratory/heart
Stomach
Psychiatric disorders (%)
Alcoholism
Cannabis abuse
Tobacco dependence
Agoraphobia
Simple phobia
Social phobia
Neurasthenia
+ Anx/dep
(N = 32)
500
21-9
52-9
32-0
281
43-8
9-4
31
62-6
6-3
6-3
9-4
* /><005
Neurasthenia
only
(N = 57)
37-3
23-5
351
43-8
15 7
25-5
3-9
20
41-2
20
11-8
3-9
; • • /»< 0-01.
Anx/dep
only
(N = 74)
37-8
13-5
44-4
25-8
10-8
20-3
81
2-8
41-7
2-8
10-8
4-2
Neither
(N = 267)
31-8
9-4 ••
34-3
23-3*
6-7**
10-5**
2-3*
0-4
25-8"
1-5
8-6
2-7
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Table 6. FP I scores by neurasthenia comorbidity groups in 1988
Scale scores
Nervousness
Aggressiveness
Depression
Irritability
Sociability
Resilience
Aggressive reaction
Inhibition
Openness
Factor scales
Aggressiveness
Extra version
Neuroticism (autonomic lability)
Neurasthenia
+ Anx/dep
(AT = 32)
Mean (s.D.)
22-9 (8-77)
21-5 (7-51)
22-0 (8-30)
25-9 (807)
20-3 (7-63)
13-4(9-41)
191 (7-63)
21-9(9-01)
19-7(6-14)
22-2 (7-72)
17-3(8-08)
23-4 (7-65)
Neurasthenia
only
(AT =51)
Mean (s.D.)
20-5 (7-63)
16-4(5-92)
16-6(6-98)
230 (804)
18-6(816)
13-7(7-76)
171 (6-97)
21-7(8-89)
19-0(7-55)
18-9(6-74)
16-3(8-00)
20-1 (7-44)
Anx/dep
only
{N = 74)
Mean (S.D.)
18-5 (7-25)
18-3 (6-95)
17-4(804)
21-9(818)
19-5(803)
12-8(8-82)
17-3(7-16)
21-4(8-67)
180(801)
18-8(7-07)
17-1 (7-96)
18-5(7-31)
Neither
(N = 267)
Mean (s.D.)
151 (5-52)*
15-2(6-82)*
121 (6-33)*
19-5(800)*
20-6 (7-28)
16-6(7-57)*
15-4(7-43)*
18-2(8-40)**
16-7 (806)
16-6(7-20)**
19-2(7-59)*
14-7(5-92)***
t / transformed (mean = 20, s.D. = 8).
• /><0-05;** / > < 0 0 1 ; * * * / • < 0-001.
1979 1988
Neurasthenia
only (N=33)
14% Neurasthenia + Affective/anxiety disorder
31 % Neurasthenia only
21 % Affective/anxiety disorder only
34% Neither
8 % Neurasthenia + Affective/anxiety disorder
25 % Neurasthenia only
17% Affective/anxiety disorder only
50% Neither
FIG. 2. Ten-year follow-up of subjects with neurasthenia only or affective/anxiety disorder only.
Affective or
anxiety disorder
only (N-110)
professional treatment for their condition. In
contrast, only 23 % of the pure neurasthenics
had sought professional treatment.
Comorbidity
Table 5 presents the cross-sectional association
between neurasthenia and other somatic and
psychiatric syndromes at age 30. Because the
concept of neurasthenia includes both physical
and mental weakness, the SPIKE interview,
which assessed a variety of somatic conditions
as well as psychological conditions, was an ideal
source of data on this condition. Neurasthenia
was associated with numerous somatic condi-
tions including migraine, stomach disturbances,
circulation problems, cardiac and respiratory
disturbances. However, other conditions
assessed, including back problems, were not
associated with neurasthenia, thereby suggesting
that these subjects are not simply exhibiting a
tendency to somaticize across all systems.
The associations between neurasthenia and
the major psychiatric disorders are also shown
in Table 5. Because major depression, dysthymia,
panic disorder, and generalized anxiety were
included in the group definitions, the analyses
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shown in this table include only the phobic
disorders and substance abuse. Alcoholism was
elevated only among the subjects with
depression/anxiety disorders with or without
neurasthenia, with a four-fold elevation in the
rates of alcoholism compared to that of controls.
For all other disorders except simple phobia, the
non-comorbid groups exhibited intermediate
rates between the comorbid and the controls.
Personality
The factor and scale scores on the FPI at the
most recent interview according to the neur-
asthenic comorbidity groups are shown in Table
6. The neurasthenics had elevated scores on
nearly all scales with the exception of the
depression score. The results of the factor score
analyses revealed that the neurasthenics were
characterized by somatic symptoms, autonomic
instability, and irritability. The comorbid group
exhibited higher scores on all of these dimensions
than the pure neurasthenics. These findings
validate the symptoms endorsed by the subjects
during the diagnostic interview, because they
were assessed completely independently of the
subjects report of the cluster of symptoms which
characterized neurasthenia.
Course
The course of neurasthenia among subjects
without comorbidity at the initial interview in
1979 is presented in Fig. 2. Neurasthenia was
much more stable over the longitudinal course
than the affective disorders. Nearly one-half of
the persons with neurasthenia at the time of the
initial interview continued to exhibit neuras-
thenia at the follow-up, whereas only 25% of
the subjects with affective disorders reported
affective disorders at the follow-up. In contrast,
subjects with pure neurasthenia were equally
likely to develop an affective or anxiety disorder
during the follow-up (i.e. 35%) as were those
with only an affective or anxiety disorder at the
initial interview (i.e. 33 %).
Another indicator of the course of neur-
asthenia assessed in the interview was the
number of years over the entire study that the
subjects reported symptoms of neurasthenia.
The average duration of neurasthenia across the
entire 10-year-period was about 4 years, with the
comorbid group reporting longer duration
(mean = 4-5 years) than the non-comorbid group
(mean = 3-5 years). The age of onset of neur-
asthenia was also assessed retrospectively at the
most recent interview. The average age of onset
was estimated to be significantly earlier among
the comorbid than in the pure neurasthenics,
with the comorbid subjects reporting an average
age of onset of 17-9 and the non-comorbid
subjects reporting an average of 19-7.
DISCUSSION
The prevalence of neurasthenia defined accord-
ing to the ICD-10 criteria was 1 % across 10
years and 0-9% in 1988 for a duration of ^ 3
months, and 8-1 % across 10 years and 12% in
1988 for a duration of ^ 1 month. The duration
criterion of ^ 3 months appeared to be ex-
cessively restrictive to represent individuals with
neurasthenia in the community. Subjects with
1 month episodes of neurasthenia exhibited
sufficient differences from controls and subjects
with anxiety or depressive disorders alone to
justify a 1 month duration criterion for neur-
asthenia in community samples. However,
differences between neurasthenia alone and
those with comorbid anxiety or depressive
disorders supported the exclusion of these
conditions from the criteria for neurasthenia.
Although there was an excess of females over
the longitudinal course, cross-sectional data
indicate that a substantial proportion of males
also suffer from this condition.
Despite the low prevalence of neurasthenic
episodes of greater than 3 months duration, all
of the subjects reported chronicity of the
condition. That is, the average case with > 1
month duration reported the presence of neur-
asthenic symptoms during an average of 4 years
of the 10 years of the study. This is quite
remarkable in light of the relatively youthful age
of this cohort.
The results of the present study also suggest
that the validity of the definition would be
enhanced by the inclusion of the dimension of
sensitivity to stress. The interview data from the
present study confirmed the results of an earlier
cluster analysis (Angst & Koch, 1991) which
suggested that neurasthenia should be broadened
to include the concept of stress intolerance,
which characterized the majority of persons
with neurasthenia.
The stability of the sub-typing according to
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comorbidity for anxiety and depression was
confirmed by prospective data on the longi-
tudinal course over a decade. The pure
neurasthenics were discriminated from the co-
morbid group by differences in treatment rates,
patterns of comorbidity, and the longitudinal
stability of neurasthenia. In contrast to the
majority of previous studies of clinical samples
which consider neurasthenia as a manifestation
of underlying depression and anxiety syndromes
(e.g. Wilson et al. 1983), these findings suggest
that there is no characteristic pattern of the
order of onset of neurasthenia and affective and
anxiety disorders. In the present study, the onset
of neurasthenia was equally likely to pre-date as
it was to post-date the onset of these comorbid
conditions. In contrast to most previous clinical
studies, Hickie et al. (1990) reported that the
onset of psychological disturbances tended to
post-date the onset of fatigue in patients with
CFS.
The severity of neurasthenia was indicated by
the magnitude of subjective distress, and both
occupational and social impairment which was
reported by 80% of the cases. Likewise, in a
study of the treated prevalence of CFS, Lloyd et
al. (1990) reported that 43 % of the patients with
this syndrome were completely incapacitated.
Kroenke et al. (1988) also noted the striking
degree of dysfunction associated with fatigue in
their primary care sample. Indeed, the impact of
fatigue was similar to that of survivors of
myocardial infection, sudden cardiac death and
hypothyroidism. Aside from the magnitude of
the suffering experienced by persons with this
condition, the medical expenses and decreased
occupational productivity are associated with an
enormous indirect cost as well.
The chronicity of neurasthenia was demon-
strated by the continued manifestation of dis-
orders in more than half of the subjects over a
decade, at an average duration of 4 to 5 years.
Similar findings emerged from 1 year prospective
follow-ups of primary care patients with com-
plaints of fatigue. Kroenke et al. (1988) found
that fatigue persisted in 72 % of their patients
after 1 year and Cathebras et al. (1992) estimated
that 50-66 % of their sample exhibited chronicity
over 1 year. The magnitude, chronicity and
impairment associated with this condition in the
general population, as well as the substantial
proportion of persons in whom manifestation of
this syndrome is distinct from anxiety of
depressive disorders, suggest that neurasthenia
is a valid diagnostic entity, and should be
considered for inclusion in American diagnostic
systems.
Neurasthenia is frequently encountered in
diverse medical specialities including neurology,
psychiatry, internal medicine, cardiology, gastro-
enterology, and rheumatology, with no speciality
claiming neurasthenia within its sole domain.
This is not surprising because the disorder itself
has moved between specialities since it was first
described. For example, Beard (1869) was a
neurologist, Griesinger (1845) an internist,
Freud (1895) a psychiatrist and neurologist and
Kielholz (1957) a psychiatrist. Although het-
erogeneous aetiology is likely given the mag-
nitude and protean manifestations of this con-
dition, the treatment of choice is currently
antidepressant medications, after detectable so-
matic aetiologies have been excluded by ap-
propriate clinical or laboratory tests (Wessely &
Powell, 1989).
Despite severe levels of impairment and
distress, however, few of the pure neurasthenics
had actually consulted a professional of any
speciality for this disorder. This explanation is
supported by the finding that the neurasthenics
with affective disorders in the present study had
sought treatment more often, either because of
the severity of the concomitant manifestations
of symptoms in both domains, or the relative
availability of treatment and public awareness
of depression. The small proportion of pure
neurasthenics who seek treatment may be
associated with the mixture of somatic and
psychological features of this syndrome. In
contrast to subjects from treated samples (see
Wessely & Powell, 1989), the majority of the
neurasthenics in the present study attributed
their symptoms to psychological and somatic
factors. The psychological manifestations, when
taken together with a lack of disturbance in a
specific organ system, may impede identification
of an appropriate source of treatment. Re-
sistance to psychiatric treatment may also be an
important component of the infrequency with
which these individuals seek professional help.
These findings underscore the need for
empirical data on this syndrome from both epi-
demiological and treatment settings. Epidem-
iological data on a wider age range of subjects
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are critical to investigate the magnitude, impact,
and comorbidity in order to identify sources of
heterogeneity in its expression, as well as for
planning for health services. Further work is
necessary to study the case definition across
diverse settings. There is also a critical need for
systematic treatment studies and prospective
follow-up studies of clinical samples. The current
follow-up of this sample at age 35 will yield
information on the stability of neurasthenia and
differential patterns of course among persons
with underlying psychiatric disorders.
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